Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Cancer
AI-powered endoscope doubles detection of high-risk esophageal lesions
By
Nick Paul Taylor
Deep learning has doubled the detection of high-risk lesions during routine endoscopies in a clinical trial of more than 3,000 patients in China.
April 17, 2024
Veracyte to share bundle of genomic classifier studies at AUA 2024
By
LabPulse.com staff writers
Veracyte has announced that the American Urological Association's May meeting will feature nine sessions related to evaluations of its prostate cancer and bladder cancer genomic tests.
April 16, 2024
Lipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in study
By
Nick Paul Taylor
Blocking lipid synthesis enhanced the effect of PARP inhibitors on prostate cancer in a preclinical study, pointing to a potential way to make the treatments effective in more patients.
April 15, 2024
Urine test halves use of invasive procedure to monitor bladder cancer
By
Nick Paul Taylor
A urine test can cut the number of cystoscopies necessary to follow up high-risk bladder cancer patients without increasing the risk of recurrence, a study has found.
April 11, 2024
U.K. researchers get funding for lung cancer vaccine development
By
Matt Limb
Researchers are working to develop a lung cancer vaccine in the U.K. with 1.7 million pounds ($2.2 million) funding from leading charities.
April 4, 2024
Castle Biosciences shares melanoma test study data at SSO 2024
By
LabPulse.com staff writers
Castle Biosciences shared data from two studies on the performance of its DecisionDx-Melanoma test in patients with cutaneous melanoma at the Society of Surgical Oncology 2024 (SSO 2024) annual meeting, held March 20-23 in Atlanta.
March 26, 2024
Ibex presents new study data for AI-powered cancer diagnostics platform
By
Matt Limb
Ibex Medical Analytics is hailing positive data from studies with U.S. partners on the impact of its artificial intelligence (AI)-powered cancer diagnostic platform Galen.
March 26, 2024
Study sheds light on the organization of immune cells in tumors
By
Matt Limb
Researchers have revealed how immune cells are spatially organized within some tumors and that certain immune “hubs” may be linked to better cancer treatment responses.
March 27, 2024
Bio-Techne receives IVDR certification for chronic myeloid leukemia monitoring test
By
LabPulse.com staff writers
Bio-Techne has announced that Asuragen, part of its molecular diagnostics division, has completed class C certification under the new European Union IVDR for its QuantideX qPCR BCR-ABL IS kit for monitoring chronic myeloid leukemia.
March 22, 2024
MIT team develops genome-editing approach for cancer mutation screening
By
Matt Limb
Scientists say they have developed a method to screen cancer-associated genetic mutations more easily and quickly than any existing approach.
March 22, 2024
ChromaCode partners with the Medical College of Georgia on NSCLC assay validation
By
LabPulse.com staff writers
ChromaCode announced a partnership with the Medical College of Georgia to test the analytical and clinical performance of ChromaCode's HDPCR non-small cell lung cancer (NSCLC) biomarker assay.
March 21, 2024
Machine-learning model predicts lung and liver cancer through genome sequence changes
By
LabPulse.com staff writers
Researchers have developed a machine-learning approach that may potentially predict early-stage lung or liver cancer by detecting repetitive sequences in the genome.
March 15, 2024
Page 1 of 96
Next Page
